Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Some modern stool tests can detect around 92 percent of colorectal cancers. But colonoscopies can detect cancer -- and prevent it. Q: My doctor always encourages me to do a colonoscopy for colorectal ...

FIT checks for blood in the stool, which can indicate the presence of colorectal cancer or polyps. Patients collect stool ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

INDIANAPOLIS -- A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas ...

WEDNESDAY, May 14, 2025 (HealthDay News) -- Multitarget stool DNA test (MSDT)- and next-generation MSDT (N-G MSDT)-based screening have higher costs per detected advanced neoplasia case or early ...

Three-quarters of people prefer to do a fecal immunochemical test (FIT) rather than a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study. Unlike ...

Please provide your email address to receive an email when new articles are posted on . The number needed to screen to detect at least one advanced adenoma was higher among those with no detectable ...

Interval fecal immunochemical testing was positive in up to 17% of patients after colonoscopy regardless of polypectomy, ...

The stool-based test picks up colorectal cancers despite prior polypectomy, but many do not receive the recommended ...